Beijing Bran Pharmaceutical

Beijing Bran Pharmaceutical is a clinical-stage biotechnology company based in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics and protein degraders. The company focuses on addressing unmet medical needs in oncology and immunology through its proprietary drug discovery and Proteolysis-targeting chimera (PROTAC) platforms. Its lead candidate, BR-101, is a highly selective Bruton tyrosine kinase (BTK) inhibitor currently undergoing clinical evaluation for B-cell malignancies. Bran Pharmaceutical leverages a deep understanding of structure-based drug design to create candidates with superior selectivity and safety profiles. The firm is supported by prominent venture capital investors and aims to expand its pipeline into global markets.